Perricone, Matthew D.
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Article History
First Online: 3 June 2024
Competing interests
: C.A.L. has consulted in the past 3 years for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures and T-Knife Therapeutics, and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the glutamic-oxaloacetic transaminase 1 (GOT1)–malic enzyme 1 (ME1) pathway as a therapeutic approach (US patent 2015126580-A1, 7 July 2015; US patent 20190136238, 9 May 2019; international patent WO2013177426-A2, 23 April 2015).